前列腺癌分子影像与诊疗一体化共识
国际多学科专家在欧洲核医学协会Focus 1会议上,基于系统文献综述和改良德尔菲流程,就前列腺癌影像与放射性药物治疗形成共识。共识指出双膦酸盐骨扫描和增强CT很少被推荐,MRI和靶向前列腺癌PET常被建议但影响实践的具体情境未确立,镓-68或氟-18 PSMA PET获认可,骨靶向放射性药物姑息治疗已被镭-223等替代,影像新方法对临床结局的影响尚待确立。
要点
- 双膦酸盐骨扫描和增强CT在临床指南中很少被推荐用于多数患者。
- MRI和靶向前列腺癌PET常被建议,但影响实践的具体情境未确立。
- 骨靶向放射性药物姑息治疗已 largely 被镭-223和全身治疗替代。
核心结论
- MRI和PET-CT进步提高了影像准确性,但这些新方法对临床结局的影响尚待确立。
- 改善影像医师与临床医师沟通及临床试验设计更多多学科投入,对促进影像洞察进入临床决策至关重要。
研究设计与样本
- 欧洲核医学协会Focus 1会议召集肿瘤内科、泌尿外科、放射肿瘤、放射和核医学专家,基于系统文献综述和改良德尔菲流程形成共识。
主要发现
- 双膦酸盐骨扫描和增强CT在临床指南中被提及但很少推荐用于多数患者。
- MRI(全身或mpMRI)和靶向前列腺癌PET常被建议,但影响实践的具体情境未确立。
- 氟-18氟化钠PET-CT骨扫描未被广泛提倡,镓-68或氟-18 PSMA获认可。
- 骨靶向放射性药物(铼-186、钐-153或锶-89)姑息治疗已 largely 被镭-223替代,基于前瞻性试验报告的生存获益及有其他证实生存获益的全身治疗。
局限性
- 影像新方法对临床结局的影响尚待确立。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Rapid developments in imaging and treatment with radiopharmaceuticals targeting prostate cancer pose issues for the development of guidelines for their appropriate use. To tackle this problem, international experts representing medical oncologists, urologists, radiation oncologists, radiologists, and nuclear medicine specialists convened at the European Association of Nuclear Medicine Focus 1 meeting to deliver a balanced perspective on available data and clinical experience of imaging in prostate cancer, which had been supported by a systematic review of the literature and a modified Delphi process. Relevant conclusions included the following: diphosphonate bone scanning and contrast-enhanced CT are mentioned but rarely recommended for most patients in clinical guidelines; MRI (whole-body or multiparametric) and prostate cancer-targeted PET are frequently suggested, but the specific contexts in which these methods affect practice are not established; sodium fluoride-18 for PET-CT bone scanning is not widely advocated, whereas gallium-68 or fluorine-18 prostate-specific membrane antigen gain acceptance; and, palliative treatment with bone targeting radiopharmaceuticals (rhenium-186, samarium-153, or strontium-89) have largely been replaced by radium-223 on the basis of the survival benefit that was reported in prospective trials, and by other systemic therapies with proven survival benefits. Although the advances in MRI and PET-CT have improved the accuracy of imaging, the effects of these new methods on clinical outcomes remains to be established. Improved communication between imagers and clinicians and more multidisciplinary input in clinical trial design are essential to encourage imaging insights into clinical decision making.
引用
- Fanti S, Minozzi S, Antoch G, et al. Consensus on molecular imaging and theranostics in prostate cancer. Lancet Oncol. 2018. PMID: 30507436. doi:10.1016/S1470-2045(18)30604-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。